Improved understanding of the biology of lung cancer has resulted in the development of new biomarker-directed therapies targeting molecular alterations (eg, EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF V600E mutations), which have prolonged survival of lung cancer patients 3. Here, BRAF is linked to lung carcinoma.